Page last updated: 2024-11-12

ro 6-4563

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glibornuride: was MH 1975-92 (see under SULFONYLUREA COMPOUNDS 1975-90); use SULFONYLUREA COMPOUNDS to search GLIBORNURIDE 1975-92; an oral, sulfonylurea hypoglycemic agent which stimulates insulin secretion [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12818200
CHEMBL ID529888
CHEBI ID135545
SCHEMBL ID49695
MeSH IDM0198291

Synonyms (41)

Synonym
26944-48-9
glibornuride
endo, endo-1-((1r)-(2-hydroxy-3-bornyl))-3-(p-tolylsulfonyl)urea
benzenesulfonamide, n-(((3-hydroxy-4,7,7-trimethylbicyclo(2.2.1)hept-2-yl)amino)carbonyl)-4-methyl-, (1s-(endo, endo))-
glibornurida [inn-spanish]
1-((1r)-2-endo-hydroxy-3-endo-bornyl)-3-(p-tolylsulfonyl)urea
n-(((3-hydroxy-4,7,7-trimethylbicyclo(2.2.1)hept-2-yl)amino)carbonyl)-4-methylbenzenesulfonamide (1s-(endo,endo))-
glutril
brn 2821299
glibornuridum [inn-latin]
ro 6-4563/8
einecs 248-124-6
ro 6-4563
CHEBI:135545
ro-64563
CHEMBL529888
ro-6-4563
glibornuride [usan:inn:ban]
glibornuridum
unii-vp83e7434r
vp83e7434r ,
glibornurida
glibornuride [mart.]
glibornuride [who-dd]
glibornuride [mi]
glibornuride [inn]
glibornuride [usan]
SCHEMBL49695
glibornurid
gluboride
mfcd00869202
n-[[[(1s,2s,3r,4r)-3-hydroxy-4,7,7-trimethylbicyclo[2.2.1]hept-2-yl]amino]carbonyl]-4-methyl-benzenesulfonamide
DB08962
Q3772225
HY-17451
DTXSID001016937
1-[(1s,2s,3r,4r)-3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]-3-(4-methylphenyl)sulfonylurea
CS-0008292
MS-25871
STARBLD0016620
AKOS040741790
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (50.00)18.2507
2000's4 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.16 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]